ALNYLAM PHARMACEUTICALS, INC. (ALNY) Net margin 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) net profit margin by fiscal year — reported net income divided by reported revenue.
8.4%FY2025 · since FY2016: -869.6% → 8.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 8.4% | +20.8 pp |
| FY2024 | -12.4% | +11.7 pp |
| FY2023 | -24.1% | +85.0 pp |
| FY2022 | -109.0% | -8.0 pp |
| FY2021 | -101.0% | +73.1 pp |
| FY2020 | -174.1% | +229.1 pp |
| FY2019 | -403.2% | +613.3 pp |
| FY2018 | -1016.6% | -470.6 pp |
| FY2017 | -545.9% | +323.7 pp |
| FY2016 | -869.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice